resisttb
- Jun 2, 2022
- 1 min read

WHO issues rapid communication on updated guidance for the treatment of drug-resistant tuberculosis

A rapid communication released by the World Health Organization (WHO) Global Tuberculosis Programme has announced upcoming updates to the guidance on the treatment of drug-resistant tuberculosis (DR-TB). These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB. Read Here.

Recent Posts

See All

World TB Day 2023 Campaign Toolkit

The Stop TB Partnership today is releasing the campaign toolkit for this year’s World TB Day, 24 March 2023 Yes! We Can End TB. The theme brings attention toTB and our collective power to end TB by 20

Sutezolid with 3-drug combo appears safe and effective in multidrug-resistant TB

Adding the oxazolidinone antibiotic sutezolid to a three-drug combination appeared to be safe and effective for people with multidrug-resistant tuberculosis (TB), according to a dose-finding phase II

TAG's TB Treatment Pipeline Report Published

TAG has released its Pipeline Report regarding TB Treatment updates and results from trials completed in 2022 written by Lindsay McKenna. Read the report here!